Connect
← Return to Ivermectin for Prostate Cancer? (Being studied)
Discussion
Ivermectin for Prostate Cancer? (Being studied)
Prostate Cancer | Last Active: Sep 6 10:58am | Replies (73)Comment receiving replies
There is a clinical study going on right now in Glasgow using docetaxel and mebendazole ( similar to ivermectin) which disrupts the cellular scaffolding matrix of PCa; the cells die without it.
The study was initiated in 2019 and a result was expected in 3-4 yrs. Factor in Covid and that set it back a bit.
If you search “mebendazole for prostate cancer” you’ll find it. Definitely not mainstream and it wouldn’t be MY first choice at this stage, but down the road this could be a game changer….gotta stay in the game and keep breathing to reap the rewards of all this exciting high tech research.
Replies to "There is a clinical study going on right now in Glasgow using docetaxel and mebendazole (..."
@heavyphil, here's an article describing the research you mention
- A bold new treatment for prostate cancer could soon be available by repurposing an existing drug. https://www.gla.ac.uk/research/beacons/precisionmedicine/researchfeatures/cancerresearch/prostatecancerresearch/
It is important to note that this promising article describes research in pre-clinical trials, meaning, in mice and not yet in human trials. See @kujhawk1978's post describing research phases https://connect.mayoclinic.org/comment/1119887/
Repurposing existing drugs for cancer treatments is a focus of some research trials for good reason. As the Glasgow article states "Drug repurposing in this way is advantageous as existing drugs already have satisfactory safety records. They can therefore be fast-tracked to treat the new disease."
An exciting research area to follow for the hoepfully not so distant future. Not sure what researchers consider "soon". It might differ from a patient's definition of soon. 😕
Connect
Yes, I agree. There's a lot of very exciting stuff in the pipeline. Most of it won't end up panning out (see @kujhawk1978 's excellent summary of research stages a few posts earlier), but that's OK. We don't need them all to succeed; even if most fail, one or two successes could be enough to tip the balance for us.
(I wish I did know which 2 or 3 of the dozens of "promising" PCa treatments in early research will make it, because then I could take all of our family's savings and invest them in the company that's doing them. Even if I didn't live long enough to make millions, it would be a nice nest egg for my family. 😉 ).